Successful complete resection and recurrence-free outcome in renal cell carcinoma with vena cava tumor thrombus: Neoadjuvant immune checkpoint inhibitor (ICI)-based combination therapies

Bex, 2019, Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial, JAMA Oncol., 5, 164, 10.1001/jamaoncol.2018.5543 Bigot, 2014, Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?, World J. Urol., 32, 109, 10.1007/s00345-013-1088-1 Carlo, 2022, Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy, Eur. Urol., 81, 570, 10.1016/j.eururo.2022.01.043 Choueiri, 2021, Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma, New Engl. J. Med., 385, 683, 10.1056/NEJMoa2106391 Cost, 2011, The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus, Eur. Urol., 59, 912, 10.1016/j.eururo.2011.02.032 Hara, 2021, Pathological complete response of renal cell carcinoma with vena cava tumor thrombus to neoadjuvant TKI/IO combination therapy, Urol. Case Rep., 39 Labbate, 2019, Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy, J. Immunother. Cancer, 7, 66, 10.1186/s40425-019-0546-8 Machida, 2023, Pathological complete response to preoperative nivolumab plus cabozantinib for renal cell carcinoma with inferior vena cava thrombus: a case report, Cancer Diagn. Progn., 3, 124, 10.21873/cdp.10189 Master, 2023, Neoadjuvant nivolumab and ipilimumab for nonmetastatic renal cell carcinoma with tumor thrombus, J. Immunother. Precis. Oncol., 6, 50, 10.36401/JIPO-22-16 Méjean, 2018, Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma, New Engl. J. Med., 379, 417, 10.1056/NEJMoa1803675 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, New Engl. J. Med., 378, 1277, 10.1056/NEJMoa1712126 Okada, 2020, Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab, Int. Cancer Conf. J., 9, 88, 10.1007/s13691-020-00403-9 Otsuka, 2022, Preoperative ipilimumab/nivolumab combination therapy reduced operation risk by downstaging the inferior vena cava tumor thrombus extending to the right atrium in a metastatic renal cell carcinoma: a case report, Urol. Case Rep., 40 Shepherd, 2020, Inferior vena cava thrombectomy following complete response to nivolumab/ipilimumab for metastatic renal cell carcinoma, ANZ J. Surg., 90, 1517, 10.1111/ans.15608 Suzuki, 2021, A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib, IJU Case Rep., 4, 412, 10.1002/iju5.12362 Tobe, 2023, The efficacy of presurgical therapy with avelumab and axitinib for renal cell carcinoma with inferior vena cava tumor thrombus, Clin. Genitourin. Cancer, 15, 39 Tung, 2021, Immune checkpoint inhibitor in first-line treatment of metastatic renal cell carcinoma: a review of current evidence and future directions, Front. Oncol., 11, 10.3389/fonc.2021.707214 Uematsu, 2022, Presurgical avelumab plus axitinib in an immunosenescent octogenarian with renal cell carcinoma invading the vena cava, Urol. Case Rep., 45 Yoshida, 2022, Immune checkpoint inhibitor combination therapy for renal cell carcinomas with concomitant inferior vena cava thrombi, In Vivo (Brooklyn), 36, 1030, 10.21873/invivo.12798